The Global Commercial Team of a top 10 global biopharmaceutical company working in Immunology with a new asset in Atopic Dermatitis
The client was developing their early commercial strategy and Phase III program for an important new asset in Atopic Dermatitis in Phase II development. The strategy needed to take account of a rapidly changing and increasingly competitive market, with several other companies pursuing products in Phase II and Phase III development
Utilizing a combination of desk research and engagement interviews with key stakeholders, we created a detailed overview of future dynamics focusing on emerging competitor profiles and created analogs of related competitor product launches to predict impact.
We then designed a scenario framework containing four plausible future market futures. To stimulate thinking and competitor focus, each scenario included the potential launch strategies of the new competitors. These four scenarios were taken into a fast-paced cross- functional team Competitoroom™ to develop a comprehensive picture of the likely competitor approach in this market, as well as consequences for the asset.
The clarity over likely competitor moves in multiple market situations enabled us to support the development of a clear brand strategy, market positioning and critical success factors. Notably the work on positioning produced some different angles previously not prioritized by the client
We delivered a rapid and insightful set of practical recommendations in an executive report that fed into a senior management decision about strategy and Phase III program requirements for this critical asset. Throughout the process Cello Health supported engagement across all functions, from HEOR and Market Access, to Legal, Regulatory and Marketing- ensuring broad consensus on the future direction of the asset
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us